Hepatorenal syndrome: the clinical impact of vasoactive therapy.

about

High expression of type I inositol 1,4,5-trisphosphate receptor in the kidney of rats with hepatorenal syndrome

P2860

Q58798112-C4640C29-F7BF-45DD-9310-E11841C5F418

P2860

Hepatorenal syndrome: the clinical impact of vasoactive therapy.

Item

http://www.wikidata.org/entity/Q47773498

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Hepatorenal syndrome: the clinical impact of vasoactive therapy.

@en

Hepatorenal syndrome: the clinical impact of vasoactive therapy.

@nl

type

Item

label

Hepatorenal syndrome: the clinical impact of vasoactive therapy.

@en

Hepatorenal syndrome: the clinical impact of vasoactive therapy.

@nl

prefLabel

Hepatorenal syndrome: the clinical impact of vasoactive therapy.

@en

Hepatorenal syndrome: the clinical impact of vasoactive therapy.

@nl

P1476

Hepatorenal syndrome: the clinical impact of vasoactive therapy.

@en

P2093

Isabelle Colle

http://www.w3.org/2001/XMLSchema#string

Pierre-François Laterre

http://www.w3.org/2001/XMLSchema#string

P2860

Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury

Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group

Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.

Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study.

Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.

MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation.

P304

173-188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/17474124.2018.1417034

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29258378

http://www.w3.org/2001/XMLSchema#string

Hepatorenal syndrome: the clinical impact of vasoactive therapy.

about

P2860

P2860

Hepatorenal syndrome: the clinical impact of vasoactive therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698